A pan-histone deacetylase inhibitor was shown to inhibit BFL-1 expression in DLBCL via decreasing expression of the transcription factor WT1 and increasing expression of NOXA, which can bind and inactivate BFL-1 [63]. The gene discussed is BCL2A1; the disease is diffuse large B-cell lymphoma.